Table 1 Descriptive data of children included in the study
From: Pre- and postnatal administration of Lactobacillus reuteri decreases TLR2 responses in infants
Lactobacillus reuteri % (n/N) | Placebo % (n/N) | p-value* | |
|---|---|---|---|
Boys | 55 (16/29) | 50 (16/32) | 0.82 |
First born | 55 (16/29) | 63 (20/32) | 0.77 |
Caesarean delivery | 14 (4/29) | 3 (1/32) | 0.16 |
Birth weight (g) (mean ± SE) | 3656 ± 434 | 3469 ± 429 | 0.10* |
Birth length (cm) | 51.3 ± 2.0 | 50.6 ± 1.9 | 0.18* |
Parental smoking | 10 (3/29) | 9 (3/32) | 0.91 |
Furry pets | 7 (2/29) | 13 (4/32) | 0.51 |
Maternal atopy | 79 (23/29) | 75 (24/32) | 0.89 |
Paternal atopy | 62 (18/29) | 69 (22/32) | 0.80 |
Breastfeeding | |||
3 months, exclusive | 59 (17/29) | 78 (23/32) | 0.62 |
6 months, partial | 83 (24/29) | 78 (24/32) | 0.80 |
Antibiotics | |||
0–12 months | 34 (10/29) | 16 (5/32) | 0.18 |
12–24 months | 48 (14/29) | 53 (17/32) | 0.83 |
Day-care | |||
0–12 months | 0 (0/29) | 3 (1/32) | 0.35 |
12–24 months | 86 (25/29) | 94 (30/32) | 0.82 |
Recurrent wheeze | 3 (1/29) | 6 (2/32) | 0.63 |
Eczema | 28 (8/29) | 28 (9/32) | 0.97 |
Allergic disease | 34 (10/29) | 38 (12/32) | 0.87 |
Sensitisation | 38 (11/29) | 34 (11/32) | 0.84 |
IgE-assoc. Disease | 10 (3/29) | 16 (5/32) | 0.59 |
SPT (12 m cumulative) | 10 (3/29) | 16 (5/32) | 0.37 |
SPT (24 m cumulative) | 17 (5/29) | 16 (5/32) | 0.89 |
Egg | 10 (3/29) | 13 (4/32) | 0.81 |
Milk | 3 (1/29) | 0 (0/32) | 0.30 |
Cat | 3 (1/29) | 6 (2/32) | 0.63 |
Birch | 3 (1/29) | 3 (1/32) | 0.95 |
Spec IgE (kU/L) | 34 (10/29) | 31 (10/32) | 0.85 |
Ovalbumin | 7 (2/29) | 22 (7/32) | 0.15 |
b-lactoglobulin | 24 (7/29) | 9 (3/32) | 0.19 |
fx5 | 31 (9/29) | 28 (9/32) | 0.85 |